| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.24 | 9e-07 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-06 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.14 | 6e-06 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.14 | 8e-06 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0004 |